In addition, molecular subtype was significantly associated with treatment response; HER2-positive tumors and triple-negative breast cancers showed higher odds of achieving pCR compared to luminal subtypes, with adjusted odds ratios of 2.62 (p = 0.043) and 3.18 (p = 0.012), respectively. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.